Patent Term Extension Application for REDEMPLO (plozasiran), Patent No. 10,597,657 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-1015

Patent Term Extension Application for REDEMPLO (plozasiran), Patent No. 10,597,657

Documents

Comments

Description

OPEN

Comment Period OpensFeb 2, 2026

Type	Title	Posted	Comments	Status
Other	Letter to U. S. Patent and Trademark Office	Apr 20, 2026	--

CDER

Patent Term Extension Application

Finnegan, Henderson, Farabow,

Garrett & Dunner, L.L.P.

Arrowhead Pharmaceuticals, Inc

REDEMPLO (plozasiran)

Patent No. 10,597,657

OPEN